NRX Pharmaceuticals, Inc.
For the period ended Mar 31, 2025. Filed May 15, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 15, 2025
NRXP$2.380.0%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 6. Exhibits
| Exhibit Number | Description | Incorporation by Reference |
| 10.1 | Term Sheet, dated as of January 5, 2025, between the Company and JGS Holdings LLC | Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on January 10, 2025 |
| 10.2+ | Securities Purchase Agreement, dated January 27, 2025, by and among the Company and the purchaser signatories thereto. | Exhibit 10.2 to the Company’s Current Report on Form 8-K filed on January 29, 2025 |
| 10.3 | Consent and Waiver Agreement, dated January 27, 2025, by and among the Company and the signatories thereto. | Exhibit 10.3 to the Company’s Current Report on Form 8-K filed on January 29, 2025 |
| 10.4 | Form of Amended and Restated Securities Purchase Agreement, dated as of January 28, 2025, by and among the Company and the Investor. | Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on February 3, 2025 |
| 10.5 | Form of Second Amended and Restated Securities Purchase Agreement, dated as of February 3, 2025, by and among the Company and the Investor. | Exhibit 10.2 to the Company’s Current Report on Form 8-K filed on February 3, 2025 |
| 10.6*+ | Asset Purchase and Contribution Agreement, dated as of May 9, 2025, by and among Hope Therapeutics, Inc. and the signatories thereto. | |
| 10.7*+ | Membership Interest Purchase and Contribution Agreement, by and among Hope Therapeutics, Inc. and the signatories thereto. | |
| 31.1* | Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | |
| 31.2* | Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | |
| 32.1** | Certification of Principal Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | |
| 32.2** | Certification of Principal Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | |
| 101† | Interactive data files pursuant to Rule 405 of Regulation S-T formatted in Inline XBRL: (i) Condensed Consolidated Balance Sheets; (ii) Unaudited Condensed Consolidated Statements of Operations; (iii) Unaudited Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficit); (iv) Unaudited Condensed Consolidated Statements of Cash Flows; and (v) Notes to Unaudited Financial Statements. | |
| 104 | Cover Page Interactive Data File (formatted in iXBRL and contained in Exhibit 101) |
| + | Certain portions of this exhibit have been redacted pursuant to Item 601(b)(10)(iv) of Regulations S-K. The Company will furnish supplementally an unredacted copy of such exhibit to the Securities and Exchange Commission or its staff upon request. |
|---|---|
| * | Filed herewith. |
| ** | This certification is being furnished solely to accompany this Quarterly Report pursuant to 18 U.S.C. Section 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the registrant, whether made before or after the date hereof, regardless of any general incorporation language in such filing. |
| † | In accordance with Rule 406T of Regulation S-T, the XBRL-related information in Exhibit 101 to this Quarterly Report on Form 10-Q is deemed not filed or part of a registration statement or prospectus for purposes of sections 11 or 12 of the Securities Act, is deemed not filed for purposes of section 18 of the Exchange Act, and otherwise is not subject to liability under these sections. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| NRX PHARMACEUTICALS, INC. | ||
| Date: May 15, 2025 | By: | /s/ Jonathan Javitt |
|---|---|---|
| Chairman and Interim Chief Executive Officer | ||
| (Principal Executive Officer) | ||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| NRX PHARMACEUTICALS, INC. | ||
| Date: May 15, 2025 | By: | /s/ Michael Abrams |
|---|---|---|
| Chief Financial Officer | ||
| (Principal Financial Officer) | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.